share_log

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem 收到基於商用級 GlycoProtemim 的抗衰老精華配方
GlobeNewswire ·  03/13 21:00

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona" or the "Company") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

不列顛哥倫比亞省溫哥華,2024年3月13日(環球新聞專線)——Sirona Biochem Corp.(TSX-V:SBM)(FSE:ZSB)(場外交易代碼:SRBCF)(“Sirona” 或 “公司”)宣佈其在尋求護膚行業轉型方面取得的重大成就。其子公司TFChem已成功從其配方合作伙伴全球美容諮詢(GBC)那裏獲得了期待已久的基於GlycoProtemim的抗衰老精華的配方。這標誌着Sirona Biochem提供創新護膚解決方案的計劃邁出了關鍵一步。

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

所選配方不僅將定義品牌,還將爲更廣泛的產品奠定基礎。該團隊正在選擇精確的配方,該配方將經過標準安全性評估並用於即將進行的臨床試驗。這是爲計劃於2025年初推出的產品做準備,從而確保符合歐洲、美國和加拿大市場的監管標準。

'We are thrilled to unveil these innovative formulations for our GlycoProteMim based anti-aging serum. Our mission at Sirona Biochem is to revolutionize skincare through science and these formulations represent a significant step towards achieving that goal." reports Sirona's Chief Scientific Officer Dr Geraldine Deliencourt-Godfrey. In line with our commitment to transparency and innovation, samples of the GlycoProteMim-based anti-aging serum formulations will be distributed to prospective key stakeholders in Asia, Europe, and North America.

“我們很高興爲我們基於 GlycoProtemim 的抗衰老精華液推出這些創新配方。我們在Sirona Biochem的使命是通過科學徹底改變護膚品,這些配方是朝着實現這一目標邁出的重要一步。” 西羅納首席科學官傑拉爾丁·德利恩庫爾特-戈弗雷博士報告說。根據我們對透明度和創新的承諾,基於Glycoprotemim的抗衰老精華配方的樣本將分發給亞洲、歐洲和北美的潛在主要利益相關者。

About Sirona Biochem Corp.

關於 Sirona Biochem Corp.

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona是一家擁有專有平台技術的化妝品原料和藥物研發公司。Sirona 專門穩定碳水化合物分子,目標是提高功效和安全性。新化合物已獲得專利,可最大限度地提高收入潛力。

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

Sirona的化合物已獲得全球領先公司的許可,以換取許可費、里程碑費和持續的特許權使用費。Sirona的實驗室TfChem位於法國,獲得了多項法國國家科學獎項以及歐盟和法國政府的資助。欲了解更多信息,請訪問。

For more information regarding this press release, please contact:

有關本新聞稿的更多信息,請聯繫:

Investor Enquiries:

投資者查詢:

Christopher Hopton
Chief Financial Officer

克里斯托弗·霍普頓
首席財務官

Phone: (604) 641-4466
Email: info@sironabioche.com

電話:(604) 641-4466
電子郵件: info@sironabioche.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Forward Looking Statements

前瞻性陳述

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新聞稿包括某些可能被視爲 “前瞻性陳述” 的陳述。除歷史事實陳述外,本新新聞稿中涉及公司預計將發生的事件或事態發展的所有陳述均爲前瞻性陳述。前瞻性陳述不是歷史事實,通常但並非總是以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在” 和類似表達方式來識別,或者說事件或條件 “將”、“將”、“可能” 或 “應該” 發生。儘管公司認爲此類前瞻性陳述中表達的預期是基於合理的假設,但此類陳述並不能保證未來的業績,實際業績可能與前瞻性陳述中存在重大差異。可能導致實際業績與前瞻性陳述中存在重大差異的因素包括市場價格、資本和融資的持續可用性以及總體經濟、市場或商業狀況。提醒投資者,任何此類陳述都不能保證未來的業績,實際業績或發展可能與前瞻性陳述中的預測存在重大差異。前瞻性陳述基於公司管理層在陳述發表之日的信念、估計和觀點。除非適用的證券法有要求,否則如果管理層的信念、估計或觀點或其他因素髮生變化,公司沒有義務更新這些前瞻性陳述。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論